-
Mashup Score: 3ViaLase CEO talks innovations in glaucoma treatment - 3 year(s) ago
Tibor Juhasz, CEO of ViaLase, Inc, discusses the company’s development of a novel, noninvasive high-resolution OCT image-guided femtosecond laser technology for the treatment of open-angle glaucoma.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 2
CXL is safe, effective to perform on younger population, study results show.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
CXL in #pediatric and young adult patients with #keratoconus can stabilize, and even improve, #corneal keratometry, vision out to 2 years postoperatively, new study results show. https://t.co/IIBDLMUWSo #Ophthalmology #ASCRS2021 #ASCRS @ByersEye @StanfordMed @StanfordHealth https://t.co/xLCBwXrf3z
-
-
Mashup Score: 12Grail Study shows refractive stability of Juvene IOL - 3 year(s) ago
Eric Donnenfeld, MD, presents results of the year-long Grail Study demonstrating the safety and performance of the Juvene IOL from LensGen Inc.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
. @DonnenfeldEric presents results of the year-long Grail Study demonstrating the safety and performance of the Juvene #IOL from LensGen Inc. https://t.co/cR6zUyN7hv #Ophthalmology #ASCRS #Cataract #Refractive #ASCRS2021
-
-
Mashup Score: 3Aurion Biotech: Treating endothelial disease with one donor - 3 year(s) ago
Edward Holland, MD, discusses Aurion Biotech’s investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
WATCH: Edward Holland, MD, discusses @AurionBiotech's investigation of an injectable technique where one #cornea donor could potentially supply hundreds of patients with treatment for #endothelial disease https://t.co/GgffxCEd7a #Ophthalmology #Corneal #ASCRS #ASCRS2021 https://t.co/Yv8QJyRuZc
-
-
Mashup Score: 1ViaLase CEO talks innovations in glaucoma treatment - 3 year(s) ago
Tibor Juhasz, CEO of ViaLase, Inc, discusses the company’s development of a novel, noninvasive high-resolution OCT image-guided femtosecond laser technology for the treatment of open-angle glaucoma.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
WATCH: Tibor Juhasz, CEO of ViaLase, Inc, discusses the company's development of a novel, noninvasive high-resolution #OCT image-guided femtosecond laser technology for the treatment of #glaucoma. https://t.co/HWvFFlQfSF #Ophthalmology #ASCRS #ASCRS2021 #ViaLase https://t.co/Xg3bvUd83W
-
-
Mashup Score: 7CXL effects remain generally stable 10 years post-treatment - 3 year(s) ago
Steven Greenstein, MD, reports on results of epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients 10 years after undergoing laser refractive surgery.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Steven Greenstein, MD, reports new study results showing #CXL effects remain generally stable in keratoconus and ectasia patients 10 years post-laser refractive #surgery. #ASCRS2021 https://t.co/4kjkdpEDyQ #Ophthalmology #ASCRS #Cornea @KeratoconusUS https://t.co/gGGxqtG6jS
-
-
Mashup Score: 6
CXL is safe, effective to perform on younger population, study results show.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
CXL in #pediatric and young adult patients with #keratoconus can stabilize, and even improve, #corneal keratometry, vision out to 2 years postoperatively, new study results show. https://t.co/6teZjsav2M #Ophthalmology #ASCRS2021 #ASCRS @ByersEye @StanfordMed @StanfordHealth https://t.co/yr02DqPtFJ
-
-
Mashup Score: 3RVL Pharmaceuticals: Shifting toward ocular aesthetics - 3 year(s) ago
COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
WATCH: JD Schaub discusses how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®. See the full interview: https://t.co/Lz234f509b #ASCRS #ASCRS2021 #RVL #Ophthalmology #Ocular https://t.co/dLfuBob6MY
-
-
Mashup Score: 2
Eric Donnenfeld, MD, highlights study results exhibiting risuteganib as a potential treatment option for dry eye disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
. @DonnenfeldEric explores risuteganib for DED: Promising treatment with increased TBUT, low staining scores: https://t.co/1Qa7lw0wOh #Ophthalmology #DryEyeDisease #DED #ASCRS #ASCRS2021: https://t.co/kD9ZBZfGvk
-
-
Mashup Score: 1Evaluating risuteganib for dry eye disease treatment - 3 year(s) ago
Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island (Garden City, NY), discusses highlights from his presentation of trial results analyzing risuteganib as a potential treatment for dry eye disease. Read more about the trial results here
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
WATCH: Eric Donnenfeld, MD (@DonnenfeldEric), discusses trial results analyzing risuteganib as a potential treatment for #DryEyeDisease. https://t.co/BQ5bEzNhwb #Ophthalmology #DryEye #ASCRS #ASCRS2021 https://t.co/0cUnD8wTZh
-
WATCH: Tibor Juhasz, CEO of #ViaLase, Inc, discusses the company's development of a novel, noninvasive high-resolution #OCT image-guided femtosecond laser technology for the treatment of #glaucoma. https://t.co/mXdiJ0ymjF #Ophthalmology #ASCRS #ASCRS2021 https://t.co/IbMwNEJ501